For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Renal Redox Stress and Remodeling in Metabolic Syndrome, Type 2 Diabetes mellitus, and Diabetic Nephropathy: Paying Homage to the PodocyteHayden M.R.a · Whaley-Connell A.a · Sowers J.R.a, b
Departments of aInternal Medicine and bPhysiology and Pharmacology, University of Missouri School of Medicine, Columbia, Mo., USA Corresponding Author
Prof. Melvin R. Hayden, Department of Internal Medicine, Division of Endocrinology,
Diabetes and Metabolism, Diabetes and Cardiovascular Disease Center
University of Missouri Columbia, Missouri, Health Sciences Center, MA410, DC043.00
Columbia, MO 65212 (USA)
Tel. +1 573 346 3019, E-Mail email@example.com
Type 2 diabetes mellitus has reached epidemic proportions and diabetic nephropathy is the leading cause of end-stage renal disease. The metabolic syndrome constitutes a milieu conducive to tissue redox stress. This loss of redox homeostasis contributes to renal remodeling and parallels the concurrent increased vascular redox stress associated with the cardiometabolic syndrome. The multiple metabolic toxicities, redox stress and endothelial dysfunction combine to weave the complicated mosaic fabric of diabetic glomerulosclerosis and diabetic nephropathy. A better understanding may provide both the clinician and researcher tools to unravel this complicated disease process. Cellular remodeling of podocyte foot processes in the Ren-2 transgenic rat model of tissue angiotensin II overexpression (TG(mREN-2)27) and the Zucker diabetic fatty model of type 2 diabetes mellitus have been observed in preliminary studies. Importantly, angiotensin II receptor blockers have been shown to abrogate these ultrastructural changes in the foot processes of the podocyte in preliminary studies. An integrated, global risk reduction, approach in therapy addressing the multiple metabolic abnormalities combined with attempts to reach therapeutic goals at an earlier stage could have a profound effect on the development and progressive nature to end-stage renal disease and ultimately renal replacement therapy.
© 2005 S. Karger AG, Basel
Diabetes mellitus is the leading cause for end-stage renal disease (ESRD) in the US and abroad. In 1999, 31.8% of all registered ESRD cases in the US were attributed to diabetic nephropathy (DN) . In 2001, DN accounted for 43% of new cases with ESRD in the US [2, 3]. DN develops in approximately 35% of type 1 diabetes mellitus (T1DM) and 15–20% of patients with type 2 diabetes mellitus (T2DM). At least 90% or greater of all diabetics have T2DM and in the past decade (due to the exponential growth and improved survival rates following cardiovascular events) T2DM now represents the largest number of patients with ESRD at a cost of 15.6 billion dollars per year.
ESRD in patients with T2DM may be viewed as a disease of medical progress due to the improved treatment of hypertension and coronary heart disease. More patients with T2DM now live long enough for nephropathy and ESRD to develop . A recent study demonstrated a higher incidence of DN in T2DM than in T1DM (44.4% vs.20.0%) in a group of 17,256 early-onset Japanese diabetic patients . Patients with T2DM developing ESRD requiring renal replacement therapy are increasing in all countries making this situation one of global importance [4, 6]. Therefore, it is crucial to better understand and take the necessary aggressive-preventive measures to slow this progressive disease process. Most diabetic ESRD patients die of cardiovascular disease (CVD). Thus, we need to realize that intimal redox stress, endothelial dysfunction and accelerated atherosclerosis are increased in these patients [7,8,9].
Diabetic nephropathy (DN) is a clinical syndrome of albuminuria, declining glomerular filtration rate, hypertension, and an increased CVD risk that is 2- to 4-fold higher in both T1DM and T2DM patients [4,10,11,12]. Pathological changes consist of glomerular, renovascular, and tubulointerstitial remodeling (fig. 1, 2). The basic lesion is a pronounced thickening of the basement membrane of glomerular capillaries (GBM), arterioles, collecting tubules and tubulointerstitial fibrosis. Additionally, there are changes of inflammation with monocyte-derived macrophages, as well as, mesangial cell hyperplasia and marked mesangial matrix expansion within the glomeruli. Recently, podocyte cellular remodeling of the endothelial GBM interface has garnered a great interest.
While the large majority of patients with T2DM and microalbuminuria (75–80%) have the classic DN lesions with the associated Kimmelstiel-Wilson changes, approximately 20% have nonspecific vascular (hyaline arteriolosclerosis and or hyperplastic arteriolosclerosis) changes associated with tubulointerstitial fibrosis and minimal or no glomerular changes. These changes are associated with pre or co-existing hypertension and ischemia due to systemic or intraglomerular hypertension and the associated macrovascular accelerated atherosclerosis (atheroscleropathy). Additionally, renal artery stenosis with associated cholesterol microembolism may play a significant role in this later process [13, 14].
This review focuses on renal redox stress and how this interacts with the metabolic toxicities of insulin resistance, impaired glucose tolerance, obesity, hypertension, and dyslipidemia (i.e. cardiometabolic syndrome or cardiorenal metabolic syndrome) to result in this unique milieu with its associated remodeling of the intra-renal vasculature, the glomerulus, and the tubulointerstitium. Patients with diabetic ESRD (80% or greater) die as a result of CVD. Therefore, it is necessary to relate the parallel processes of diabetic glomerulosclerosis and diabetic accelerated atherosclerosis of T2DM (table 1). This parallel process is largely due to the similarly shared injurious stimuli to the endothelium, which places the endothelium in a central role of renal redox stress and remodeling (fig. 3) [7,8,9, 15].
Oxidation of organic fuels results in the transference of electrons between oxygen species providing energy for each cell. Redox homeostasis describes the normal physiologic process of reduction and oxidation in order to re-pair unstable, damaging, reactive oxygen species (ROS). This homeostatic balance between ROS and antioxidant capacity is in contrast to redox stress. Redox stress (redox imbalance) implies a loss of this unique homeostasis resulting in an excess production of ROS either through the process of reduction or oxidation. There exists a reductive stress in hyperglycemic conditions of overt T2DM and prediabetes, wherein there is a reductive stress (pseudohypoxia) as NADH is greater than NAD+ [7,8,9]. Oxidative stress implies a loss of redox homeostasis (imbalance) with an excess of ROS by the singular process of oxidation.
It has been known for some time that ROS are detrimental and toxic to cells and tissues as a result of injury to lipids, nucleic acids, and proteins: (a) Lipid peroxidation of membranes (loss of membrane function and increased permeability) and generation of lipid autoperoxidation reactions. (b) DNA damage leading to mutation and death (apoptosis). (c) Cross-linking or vulcanization of sulfhydryl-rich proteins leading to dysfunctional signaling pathways and stiff aged proteins (specifically, collagen of the extracellular matrix) [7,8,9, 16]. Throughout this review, we will attempt to remain focused on the relationship between redox stress and ROS in the re nal architecture, and how these two interact with the multiplicative effect of the A-FLIGHT-U toxicities (table 2) of the MetS which are responsible for increased ROS production. When redox homeostasis transitions to redox stress, redox signaling ensues in all tissues and organs regardless of the multiple similar or dissimilar etiologies due to redox stress being a redox signaling system [17, 18]. An elegant discussion of the cellular oxidative processes in renal disease has recently been published for a more in-depth view of these complex mechanisms .
Endothelial nitric oxide (eNO) is derived from the endothelial nitric oxide synthase (eNOS) enzyme reaction converting L-arginine to NO plus L-citrulline (fig. 4). eNO is a constitutive, locally produced, naturally occurring chain breaking antioxidant (anti-redoxidant) that scavenges locally produced ROS. Once conceptualized that a specific and unique gene (eNOS, iNOS, and nNOS) encodes the transcription of nitric oxide in a specific organ system, the opposing faces of this highly specialized, small, bioactive, and readily diffusible gas can be better understood . The healthy endothelium is a net producer of eNO; however, in the metabolic milieu of the MetS and T2DM with endothelial dysfunction there is a net production of ROS associated with DN.
Remodeling is a structural rearranging-adaptive process that occurs in a long- term, chronic response to changes in hemodynamic conditions or the effects of injurious stimuli (fig. 3). The paradox is that this process may become a disease entity, in and of itself, resulting in the actual disease process of fibrotic scarring due to chronic injurious stimuli. This happens usually when there is loss of control of the remodeling process and the extracellular matrix (ECM) always seems to play a pivotal role in this maladaptive process. By correcting the loss of redox and metabolic homeostasis and decreasing the multiple injurious stimuli (A-FLIGHT-U toxicities of the MetS, T2DM and DN), clinicians and researchers may be able to better control the remodeling changes that are so destructive to the end-organ tissues affected in the clinical syndrome of DN [7,8,9].
Metabolic syndrome (MetS) affects approximately 47 million plus Americans . Of these 47 million, approximately 20% will develop T2DM and the remaining 80% will be able to compensate (at least for a period of time) through the process of beta cell expansion, hypertrophy, and hyperplasia (utilizing the replicative pool of periductal cells) [21, 22]. The resulting hyperinsulinemia, hyperproinsulinemia, and hyperamylinemia (37.6 million) does not come without a price to pay as this compensatory mechanism places these patients at risk for CVD [23, 24]. Insulin resistance (IR) describes the condition, whereby; there is a resistance to insulin-mediated glucose uptake by cells and is central to the clustering of multiple metabolic abnormalities and clinically the MetS (fig. 5). The World Health Organization closely parallels the NCEP ATPIII guidelines; however, it includes microalbuminuria that conveys the significance of DN to the metabolic milieu of the MetS [24, 25].
The obesity epidemic is of considerable importance and is closely related to the T2DM epidemic (diabesity). There is accumulating evidence that obesity contributes to glomerular injury. In an obese canine model at 8 weeks fed a high-fat diet there is considerable glomerular remodeling . The obese dogs had the following remodeling changes: an increase in kidney weight by 31 ± 7%, a significant increase in Bowman’s space, increased mesangial matrix and thickening of glomerular and tubular basement membranes, and an increase in the number of dividing cells within the glomerulus. These early remodeling changes associated with obesity may therefore be significantly important in the long term remodeling process of glomerulosclerosis and DN. Similar renal changes are found in the Zucker obese model of T2DM discussed later.
The multiple metabolic A-FLIGHT-U toxicities acronym was created to enable the reader to better understand the relationship of the multiple toxicities to the development of renal redox stress, ROS and renal cellular and extracellular matrix remodeling [27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65].
For a detailed discussion of each individual component of the A-FLIGHT-U acronym, the reader is referred to references [7,8,9,62,63,64,65]. Additionally, it should also be noted that the multiple toxicities found within table 2 apply to each of the multiple complicating diabetic opathies and their respective remodeling adaptations.
While an in-depth discussion of each of the A-FLIGHT-U toxicities is not within the scope of this review, a discussion of antioxidant enzymes, glucotoxicity, endothelial dysfunction-endothelial nitric oxide, proteases, hypertension, and electron micrographic observations of podocyte foot processes in an over expressing angiotensin II model (Ren-2) and the Zucker obese model were felt necessary to better understand the role of MetS, IR and T2DM in renal redox stress and remodeling in DN.
In addition to the excess generation of the ROS seen in T2DM and the MetS, there exists an impaired generation of endogenous antioxidants. Superoxide dismutase (SOD) [66,] glutathione reduced (GSH) [67,] and ascorbic acid (vitamin C)  are all decreased and associated with endothelial dysfunction and DN. Moreover, there is evidence of a diminished capacity of other antioxidants such as vitamin E with a reduced activity of catalase and glutathione peroxidase . The exact mechanisms of impairment are still not completely understood but two hypotheses exist.
Protein glycation with resultant advanced glycation end-products (AGEs) may be a mechanism that damages the protein within the primary antioxidant enzymes, and the antioxidant enzymes, which are co-dependent on one another, may be dysfunctional if one or the other is being consumed by an overactive demand.
The absence of network antioxidant enzymes could play an additional role. In an eNOS knockout mouse model insulin resistance, hyperlipidemia, and hypertension were present in mice lacking the specific isoform eNOS . This represents the loss of the naturally occurring oxygen free radical scavenging – antioxidant effect of eNO. In the MetS and T2DM, this would not require a complete absence of the eNOS enzyme and there is evidence of a gene polymorphism in humans. Investigators have been able to demonstrate that a gene polymorphism (Glu298→Asp in exon 7 of the eNOS gene) was associated with coronary spastic angina, myocardial infarction and found further evidence for this gene polymorphism in the statistically significant association with the development of essential hypertension in two separate Japanese populations  Additionally, another group has shown a significant association of the Glu298→Asp gene polymorphism and ESRD in T2DM, which once again points to the importance of the endothelial cell and the eNOS reaction in DN .
Asymmetrical dimethylarginine (ADMA), initially found in patients with renal insufficiency, has recently been shown to be associated with endothelial dysfunction and increased risk of CVD [73,74,75,76,77,78,79,80]. Researchers have been able to demonstrate a positive correlation with impaired insulin-mediated glucose disposal and elevated levels of ADMA . Plasma ADMA concentrations are increased in insulin-resistant subjects independent of hypertension and act as a competitive inhibitor of the L-arginine substrate in the eNOS reaction. Increases in plasma ADMA concentrations may contribute to the endothelial dysfunction observed in insulin-resistant individuals. Elevated levels of ADMA have been observed in insulin resistance – hyperinsulinemia, hypertension, dyslipidemia, hyperhomocysteinemia, and chronic kidney disease. ADMA is formed by protein arginine N-methyltransferases (PRMT) and LDL-cholesterol (both native and oxidized) upregulates PRMTs increasing ADMA [73, 74]. Under physiologic conditions, eNOS is the endothelial constitutive (rate-limiting) enzyme responsible for the conversion of L-arginine to NO and L-citrulline. It requires a cofactor tetrahydrobiopterin (BH4). There is a paradoxical uncoupling of the eNOS enzyme that allows this above reaction to be capable of producing superoxide if there is insufficient BH4, L-arginine, or if there is direct interference with and/or defect in the eNOS enzyme. Uncoupling of the eNOS enzyme results in the production of damaging superoxide, which adds to the oxidative stress within the arterial vessel wall and the glomerular capillary endothelium. Causative factors for eNOS uncoupling are as follows: Increased O2– and peroxynitrite, elevations in glucose, native LDL-cholesterol and oxidatively modified (mmLDL-cholesterol), hyperhomocysteinemia, decreased or impaired cofactor BH4, decreased L-arginine, increased ADMA, and C reactive protein (fig. 6). Additionally, the diabetic endothelium has been shown to be a net producer of superoxide instead of eNO resulting in a decreased ratio of eNO/ROS (fig. 4, 6), [9,75,76,77,78,79]. Uncoupling of the eNOS reaction is likely an important process contributing to renal redox stress and remodeling [76,77,78,79,80,81].
DN is associated with both type 1 and type 2 diabetes mellitus and similarly shares oxidative-redox stress. In the MetS and early T2DM the compensatory hyperinsulinemia, hyperproinsulinemia, and hyperamylinemia due to insulin resistance result in an activation of a local-tissue renin-angiotensin-aldosterone system (RAAS) and specifically angiotensin II (Ang II) with resultant redox stress. Once hyperglycemia has developed, it is responsible for not only a reductive stress (NADH greater than NAD+) but also the increase in local-tissue Ang II, which induces oxidative stress and endothelial damage associated with vasoconstriction, thrombosis, inflammation and renovascular remodeling associated with DN.
Four subsections are important in the discussion of glucotoxicity and include advanced glycosylation endproducts, receptor for advanced glycosylation endproducts (the AGE-RAGE connection), glucose auto-oxidative reactions, the polyol-sorbitol pathway and the diacylglycerol-proteinkinase C isoform (DAG-PKC) pathway, and the direct scavenging of glucose on nitric oxide via glucotoxicity [7,8,9]. Each is important in the production of excessive ROS contributing to the multiple microvascular complications and specifically DN.
Htn is associated with increased redox stress (ROS) and is associated with ROS mediated vascular damage, which is closely associated with the activation of Ang II and its effect on the vascular NAD(P)H oxidase-superoxide generating enzyme [31, 32]. The major enzymatic sources are NAD(P)H oxidase, xanthine oxidase and paradoxically the eNOS enzyme (in the presence of oxidative stress or deficiency of L-arginine or tetrahydrobiopterin, and eNOS uncoupling) [84, 85]. It is important to note that glucotoxicity is closely associated with activation of the RAAS at the local interstitial and tissue levels. Recently, amylin has been implicated as being elevated in patients who have a positive family history associated with Htn and is elevated prior to the onset of Htn when insulin remains at normal levels. Thus, amylin levels may become a screening tool for the development of future Htn . Htn is associated with the clustering phenomenon of the MetS and its importance to the overall picture of redox stress is not to be underestimated, as it contributes significantly to renal remodeling and the overall morbidity and mortality associated with T2DM and DN [87,88,89,90].
Each of the major players in the MetS (fig. 5) plays a significant role in the development of CVD, T2DM, and DN. Central to each diabetic complication is the presence of vascular abnormalities of the endothelium and associated endothelial dysfunction (ED).
Other factors that may be of importance are: oxidized LDL-cholesterol, low HDL-cholesterol, interferon gamma, TNF-α, VEGF, TGF-β, PDGF, IGF-1, and IL-1 . Each has been shown to play a detrimental role in the development of DN.
IR, Htn, and T2DM, along with progression to microalbuminuria (MAU) and DN are associated with progressive ED. The vascular and glomerular endothelium normally controls VSMC and mesangial cell tone, and limits leukocyte adhesion, generation of ROS, and inflammatory activity. This is mediated in part by the actions of endothelial derived factors such as NO, prostaglandins, endothelin, von Willebrand factor, soluble thrombomodulin, soluble adhesion molecule and plasminogen activator inhibitor (PAI-1) .
ED is present when these functions are altered and allow for the vascular endothelium to be more permeable to the pro-inflammatory modulators and have increased interactions with leukocytes, adhesion molecules, and chemoattractants. Once ED is present, this can initiate and allow for accelerated atherosclerosis throughout the vasculature. DN produces a pro-inflammatory state to allow endothelial dysfunction (both in the glomerular endothelium and the systemic vasculature) to result in an overall increased risk for CVD and renal redox stress and remodeling .
Elevated redox stress is associated with an increase in matrix MMP activity, especially the inducible MMP-9 . The observation that MMPs are activated when eNO is decreased and MMPs are quiescent when eNO is in the normal physiologic range is of great interest when considering eNOS dysfunction.
Cells are dependent on integrin matrix ligand-binding sites and MMP-9 is a basement membrane degrading enzyme capable of clipping the integrin matrix ligands. Cells are constantly re-establishing new integrin matrix binding sites; however, if there is a complete disconnection of integrin matrix binding sites due to a robust increase in MMP-9, the cell may undergo apoptosis. Not only is MMP-9 elevated in diabetes but also redox stress was shown to play a very important role .
A robust activation of MMP-9 may result in a complete disconnection of the renal cells within the glomerulus (endothelial cell, mesangial cell and podocyte) and the proximal renal tubule resulting in atrophy, dysfunction, apoptosis, cytoskeleton rearrangement and ECM remodeling. Hearts of mice treated with alloxan have demonstrated increased endothelial cell apoptosis and decreased endothelial cell density . Decreased NO, increased peroxynitrite, and ROS in these same animals were found and thus linked the importance of vascular cellular apoptosis, MMP-9 and redox stress. In contrast, alloxan-induced diabetes in MMP-9 knockout mice did not have induced endothelial cell apoptosis and did not have decreased endothelial cell density when compared to wild type alloxan-induced diabetes. In this same model there was an interesting unpublished observation: The wild-type mouse displayed decreased glomeruli, whereas glomeruli in the MMP-9 knockout mouse were preserved. With a robust activation of MMP-9, the basement membrane and supporting ECM could be degraded allowing a cellular disconnect to occur. These findings may help explain the structural changes of podocyte foot processes, their atrophy, apoptosis and shedding. The partial or complete disconnect of glomerular cells could contribute to the collapse of the glomerulus if there were a robust activation of MMP-9. These observations could relate redox stress, inflammation, MMP-9 and cellular disconnect together resulting in glomerular failure and collapse as observed with cellular separation and disconnect in hooves of laminitic equine models . Additionally, the SHR rat model demonstrated that MMP-2 and MMP-9 were activated in the kidney .
In addition to being collagenolytic these gelatinases are elastinolytic and in the presence of redox stress could contribute to mesangial stalk weakening and collapse along with the loss of structural support of the podocyte and its strengthening foot processes supporting the glomerular mesangium.
It will be interesting to see if MMP-9 gene polymorphisms may be playing a significant role in the development of DN. A recent study indicates that a Japanese patient population with T2DM who have the A21 allele of the MMP-9 gene may be protected from the development and progression of DN . Also, it will be interesting in the near future to see if the newly developed MMP-9 inhibitors or the tetracycline family (specifically doxycycline) could have a positive clinical outcome in preventing proteinuria, podocyturia and ESRD.
An association of MAU and epithelial dysfunction in diabetics has recently been reported and furthermore it was determined that increased plasma MMP-9 preceded the occurrence of MAU in diabetic patients [99, 100]. Additionally, it has been reported that endothelial dysfunction preceded MAU in diabetics  and MMP-9 expression correlated with the period of proteinuria in Heymann nephritis . A direct link seems to exist between glomerular and epithelial cell proteolytic activities associated with the loss of glomerular permselectivity and proximal tubule reabsorption of protein. It has been speculated that one of the sources of increased plasma MMP-9 levels may be epithelial cells, and diabetic patients with podocyturia revealed elevated plasma MMP-9 concentrations .
The paradox of a low to normal plasma renin state in diabetes and the renoprotection conferred by angiotensin converting enzyme inhibitor(s) (ACEI) and angiotensin receptor blocker(s) (ARB) is largely due to a blockade of the increased activity of a local -tissue RAAS and excess Ang II activity in renal tissue in DN .
The roles of Ang II and TGF-β play a significant role in renal redox stress, cellular and ECM remodeling. Ang II contributes to the excess local renal production of TGF-β and is the most potent stimulus for the production and activation of the membranous NAD(P)H oxidase enzyme resulting in oxidative stress-ROS within the renal architecture. Each of their roles has been extensively studied and their effects within the glomerulus and the tubulointerstitium regarding the remodeling of the ECM are well known [104,105,106,107,108,109,110]
TGF-β1 has been observed to increase the activities of MMP-2 (3-fold at 10 ng/ml) and MMP-9 (25-fold at 10 ng/ml) from differentiated podocytes but did not enhance the secretion of its inhibitor, TIMP-2 . This finding supplements the proposals set forth in the preceding section regarding MMPs and redox stress. Recently, we have been able to demonstrate cellular structural remodeling of the podocyte foot processes.
Podocytes (visceral epithelial cells) share characteristics of both a mesenchymal and an epithelial cell and are thought to be terminally differentiated . ROS are known to induce an epithelial-mesenchymal transition of both the podocytes, as well as the proximal tubule and are known to possess AT-1 receptors , which are subject to the remodeling actions of the RAAS-Ang II and ROS . We have chosen to examine the podocyte in contrast to the mesangial cell (with no disrespect to the earlier held mesangiocentic view, as podocytopathy in DN only adds to the mesangial cell story in diabetic glomerulopathy) in this paper in some detail due to its recent emergent importance in glomerular filtration and observational findings of early cellular remodeling in DN. The podocyte slit diaphragm is the final filtration barrier of albumin in the glomerular endothelial basement membrane-podocyte interface. Indeed, podocytopathy is present early on in the natural history of DN and plays an important role in micro- and macroalbuminuria. Podocyturia reflects multiple metabolic toxicity mechanisms and both cellular and extracellular matrix remodeling due to redox stress . The podocyte is subject to multiple metabolic toxicities in DN including: hyperglycemia, AGE, TGF-β, Ang II, mechanical stress (increased flow and pressure-HTN) and ROS. These toxicities may result in the clipping of β1-integrins and connexons by inducible MMP-9 and result in podocyte dysfunction, injury, broadening of the foot processes with eventual effacement and separation from its matrix with resultant apoptosis and podocyturia while at the same time promoting micro- and macroalbuminuria.
Podocytes: The ‘Foot-Soldiers’ of the Glomerular Filtration Barrier
The foot-soldier is the first to be lost in military battle and the podocytes ‘foot cells’ are the first to be lost in the battle against redox stress and ROS. Thus, the podocyte foot processes may be termed the ‘foot-soldiers’ of the glomerular endothelium in regard to their role in maintaining the filtration barrier within the glomerulus. The podocyte foot processes (in health) stand to attention in an orderly formation and thus have become major players in the development of DN (fig. 7) .
Cellular structural remodeling of the podocyte is known to be present in DN and consists of cellular swelling, retraction and effacement of the distal foot processes, vacuole formation, fusion of foot processes, displacement of slit diaphragms, and detachment from the glomerular BM and podocyturia. These changes are known to be present at the onset of microalbuminuria and probably occur even earlier in the natural history of DN . In preliminary studies, we have recently observed the structural remodeling of podocyte foot processes and the glomerular filtration barrier interface. Using the Sprague-Dawley (SD) rat as a control, we compared the transmission electron-microscopic (TEM) findings to the transgenic hypertensive Ren-2 model of tissue Ang II overexpression (TG(mREN-2)27) control-untreated to Ren-2 models treated with an angiotensin receptor blocker (ARB).
In preliminary studies, utilizing the SD model as a control animal without Htn, we observed an orderly structural arrangement of the podocyte foot processes (fig. 7). We then examined the foot processes of the Ren-2 model control and found cellular remodeling of the foot processes (fig. 8, fig. 9). We then compared the TEM findings of the Ren-2 model control with that of the Ren-2 model treated with an ARB. The Ren-2-treated model, while still structurally abnormal demonstrated a marked improvement in the appearance of the foot processes and preserved filtration slits (fig. 9). While these preliminary findings are only observational structural remodeling changes, they point to the importance of Ang II within the glomerulus and the cellular remodeling of the podocyte foot processes. Additionally, they point to a possible preventive structural change utilizing an ARB. The abrogation of the structural changes may help explain the protective role of ARBs in recent clinical trials, as it has been previously shown that an ARB abrogated the oxidative stress in the Ren-2 model and resulted in improved insulin sensitivity .
Observational Findings of Cellular Remodeling in the Zucker Diabetic Fatty (ZDF) Model, Which Represents the Effects of Multiple Metabolic Toxicities: A-FLIGHT-U
Preliminary observational studies examining the podocyte endothelial GBM interface remodeling by TEM in the Zucker obese model revealed even more destructive structural-remodeling changes when compared to the Ren-2 model (fig. 10). This model, like human T2DM is characterized by the changes associated with IR, MetS, Htn and eventually overt T2DM with the associated multiple metabolic toxicities (A-FLIGHT-U). These toxicities act synergistically to result in an even greater remodeling of the glomeruli and the podocyte GBM interface. These changes may even antedate the development of micro and macroalbuminuria. This remodeling occurs early in the natural history of DN and after observing these profound TEM changes in the Zucker model one must consider the important role in taking a clinical global risk reduction approach in T2DM and DN [119,120,121,122] (table 3).
Throughout this review, we have tried to remain focused on the relationship between redox stress and ROS in the glomerular intima (mesangium), arterial intima, and how these two interact with the multiplicative effect of the A-FLIGHT-U toxicities of MetS, IR, prediabetes, and overt T2DM to induce DN and atheroscleropathy. Redox stress and ROS operate through similar mechanisms and will operate in a similar fashion in other chronic disease states, which result in cellular and extracellular matrix remodeling.
T2DM, atheroscleropathy, and DN remain a heterogeneous and manifold disease not only in their etiology but also in their manifold A-FLIGHT-U metabolic toxicities associated with MetS, IR and T2DM. If the current trend continues, due to the current epidemic of obesity-diabesity in our adolescent youth and the aging baby boom generation, these patients are going to be seen with increasing frequency and we can only expect dialysis clinics to undergo their own remodeling expansion.
Currently, potential prevention or delaying the progression of DN may be accomplished through aggressive global risk reduction of the manifold toxicities by using the currently available treatment modalities we now have at our disposal [119, 123]. Primary prevention of diabetes, secondary prevention of diabetic complications, and tertiary prevention of morbidity and mortality from established diabetic complications utilizing multiple drug targets in the management of T2DM are becoming more realistic clinically [124, 125]. Therefore, a multidisciplinary (global risk reduction) approach to utilize and implement the RAAS acronym and treatment to known goals may be in order, as this approach has seemed so successful in achieving lipid goals in chronic hemodialysis patients  (table 3).
We should consider the pleiotropic effects of HMG-CoA reductase inhibitors (statins), ACEI-ARBs, and 5-methyl tetrahydrofolate (folic acid) and tetrahydrobiopterin. Each aid in the increase of the endogenous, locally scavenging, naturally occurring antioxidant (antiredoxidant): eNO. While awaiting the availability of newer antioxidant molecules, such as the new probucol-like (phenolic analog) AGI-1067 antioxidant under development , tetrahydrobiopterin (BH4) , and the SOD and catalase mimetics, it has been suggested that thiazolinediones, statins, ACE inhibitors, and AT1 blockers should also be used because they are effective causal antioxidants . Furthermore, it has just been reported that probucol (a potent antioxidant) delays the progression of DN and thus supports the concept of renal redox stress and remodeling .
When redox homeostasis transitions to redox stress, redox signaling ensues in all tissues and organs regardless of the multiple similar or dissimilar etiologies, as redox stress is a redox signaling system resulting in cellular and ECM remodeling [17, 18, 113] (table 4). In order to understand function, it is important to understand structure (remodeling) as a result of metabolic alterations and specifically renal redox stress. The cardiometabolic syndrome goes by many names; however, to honor renal redox stress and remodeling we propose yet another name: The Cardiorenal Metabolic Syndrome.
M.R. Hayden conceived the idea to write this paper and co-authors contributed equally in the writing, and editing of the manuscript.
A part of this study was supported by the NIH, National Heart, Lung, and Blood InstituteGrant RO1 HL-63904-01 and a Department of Veterans Affairs MeritReview;James R. Sowers.
The authors wish to acknowledge the electron microscope core facility at the University of Missouri (Cheryl Jensen – electron microscopy specialist) for the excellent help and preparation of the transmission electron micrographs.
Prof. Melvin R. Hayden, Department of Internal Medicine, Division of Endocrinology,
Diabetes and Metabolism, Diabetes and Cardiovascular Disease Center
University of Missouri Columbia, Missouri, Health Sciences Center, MA410, DC043.00
Columbia, MO 65212 (USA)
Tel. +1 573 346 3019, E-Mail firstname.lastname@example.org
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.